0001169245-21-000106.txt : 20211108 0001169245-21-000106.hdr.sgml : 20211108 20211108182609 ACCESSION NUMBER: 0001169245-21-000106 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20211105 FILED AS OF DATE: 20211108 DATE AS OF CHANGE: 20211108 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Hutson Nancy J CENTRAL INDEX KEY: 0001379222 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38697 FILM NUMBER: 211389272 MAIL ADDRESS: STREET 1: 64 MONTAUK AVENUE CITY: STONINGTON STATE: CT ZIP: 06378 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: PhaseBio Pharmaceuticals Inc CENTRAL INDEX KEY: 0001169245 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 030375697 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1 GREAT VALLEY PARKWAY STREET 2: SUITE 30 CITY: MALVERN STATE: PA ZIP: 19355 BUSINESS PHONE: (610) 981-6500 MAIL ADDRESS: STREET 1: 1 GREAT VALLEY PARKWAY STREET 2: SUITE 30 CITY: MALVERN STATE: PA ZIP: 19355 FORMER COMPANY: FORMER CONFORMED NAME: Phase Biosciences Inc DATE OF NAME CHANGE: 20061013 FORMER COMPANY: FORMER CONFORMED NAME: DT BIOSCIENCES INC DATE OF NAME CHANGE: 20020315 4 1 wf-form4_163641394792074.xml FORM 4 X0306 4 2021-11-05 0 0001169245 PhaseBio Pharmaceuticals Inc PHAS 0001379222 Hutson Nancy J C/O PHASEBIO PHARMACEUTICALS, INC. 1 GREAT VALLEY PARKWAY, SUITE 30 MALVERN PA 19355 1 0 0 0 Common Stock 2021-11-05 4 M 0 24860 2.26 A 24860 D Common Stock 2021-11-05 4 M 0 1500 3.15 A 26360 D Common Stock 2021-11-08 4 M 0 7400 3.15 A 33760 D Non-employee Director Stock Option (right to buy) 2.26 2021-11-05 4 M 0 24860 2.26 D 2028-05-03 Common Stock 24860.0 2256 D Non-employee Director Stock Option (right to buy) 3.15 2021-11-05 4 M 0 1500 3.15 D 2029-02-27 Common Stock 1500.0 7400 D Non-employee Director Stock Option (right to buy) 3.15 2021-11-08 4 M 0 7400 3.15 D 2029-02-27 Common Stock 7400.0 0 D The stock option shall vest with respect to 25% of the shares on February 21, 2019, and shall vest in 36 additional monthly installments thereafter, subject to the reporting person's continued service through each such date. The shares subject to the option shall vest in equal monthly installments over 36 months from October 17, 2018, subject to the reporting person's continued service through each such date. /s/ John P. Sharp, Attorney-in-fact 2021-11-08